Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

Blood Reviews

Volumn 24, Issue 6, 2010, Pages 233-238

  Jona, Adam ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Brentuximab vedotin; Everolimus; HADC; MTOR; Panobinostat; Reed Sternberg; Rituximab; SGN 35

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CD30 ANTIGEN; DACARBAZINE; DOXORUBICIN; ENTINOSTAT; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; LENALIDOMIDE; MGC 0103; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEASOME INHIBITOR; RITUXIMAB; SDNX 275; SGN 30; SGN 35; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VINBLASTINE; VORINOSTAT;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

DRUG DELIVERY SYSTEMS; HODGKIN DISEASE; HUMANS; HYDROXAMIC ACIDS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; RECURRENCE;

EID: 78149466712     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2010.08.003     Document Type: Article

References (66)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Horning S., Fanale M., deVos S., et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort [abstract]. Ann Oncol 2008, 20:118.
3. Buglio D., Georgakis G., Younes A. Novel small-molecule therapy of Hodgkin lymphoma. Expert Rev Anticancer Ther 2007, 7:735-740.
4. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009, 9:15-17.
5. Younes A., Carbone A. CD30/CD30 ligand and CD40/ CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 1999, 14:135-143.
6. Younes A., Aggarwall B.B. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003, 98:458-467.
7. Ansell S.M., Horwitz S.M., Engert A. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-60) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007, 25:2764-2769.
8. Forero-Torres A., Leonard J.P., Younes A., et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009, 146:171-179.
9. Oflazoglu E., Kissler K.M., Sievers E.L., Grewal I.S., Gerber H.P. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemo-therapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008, 142:69-73.
10. Younes A., Forero-Torres A., Bartlett N.L., et al. Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood (ASH Annual Meeting Abstracts) 2008, 112:1006.
11. Fanale M., Bartlett N.L., Forero-Torres A., et al. The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study. Blood (ASH Annual Meeting Abstracts) 2009, 114:2731.
12. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432.
13. Heider U., Kaiser M., Sterz J. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2006, 76:42-50.
14. Wang S., Yan-Neale Y., Cai R., Alimov I., Cohen D. Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle 2006, 5:1662-1668.
15. Brogdon J.L., Xu Y., Szabo S.J. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007, 109:1123-1130.
16. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
17. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51.
18. Schwering I., Brauninger A., Klein U. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003, 101:1505-1512.
19. Ushmorov A., Ritz O., Hummel M. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 2004, 104:3326-3334.
20. Ushmorov A., Leithauser F., Sakk O. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006, 107:2493-2500.
21. Buglio D., Georgiakis G.V., Hanabuchi S. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008, 112:1424-1433.
22. Buglio D., Mamidipudi V., Khaskhely N.M., et al. The histone deacetylase inhibitor MGCD0103 down regulates CD30, activates NF-Kb, and synergizes with proteasome inhibitors by HDAC6 independent mechanism in hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 2009, 114:3735.
23. Khaskhely N.M., Buglio D., Shafer J., Bollard C.M., Younes A. The histone deacetylase (HDAC) inhibitor entinostat (SNDX-275) targets Hodgkin lymphoma through a dual mechanism of immune modulation and apoptosis induction. Blood (ASH Annual Meeting Abstracts) 2009, 114:1562.
24. Shichijo S., Yamada A., Sagawa K. Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2'- Jpn J Cancer Res 1996, 87:751-756.
25. Dickinson M., Ritchie D., DeAngelo D.J., et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol 2009, 147:97-101.
26. Sureda A., Engert A., Browett P.J., et al. Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT). ASCO Meet Abstr 2010, 28:8007.
27. Khan N., Jeffers M., Kumar S. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008, 409:581-589.
28. Beckers T., Burkhardt C., Wieland H. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007, 121:1138-1148.
29. Riester D., Hildmann C., Grunewald S., Beckers T., Schwienhorst A. Factors affecting the substrate specificity of histone deacetylases. Biochem Biophys Res Commun 2007, 357:439-445.
30. Bociek R.G., Kuruvilla J., Pro B., et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL). ASCO Meet Abstr 2008, 26:8507.
31. Kirschbaum M.H., Goldman B.H., Zain J.M. Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517 [abstract]. Blood 2007, 110:2574.
32. Ihle N.T., Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 2009, 8:1-9.
33. Franke T.F. PI3K/Akt: getting it right matters. Oncogene 2008, 27:6473-6488.
34. Georgakis G.V., Yazbeck V.Y., Li Y., Younes A. Preclinical rationale for therapeutic targeting of mTOR by CC-I779 and rapamycin in Hodgkin lymphoma [abstract]. Proc ASCO 2006, 24:10070.
35. Jucker M., Sudel K., Horn S. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 2002, 16:894-901.
36. Morrison J.A., Gulley M.L., Pathmanathan R., Raab-Traub N. Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 2004, 64:5251-5260.
37. Nagel S., Scherr M., Quentmeier H. HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. Leukemia 2005, 19:841-846.
38. Renne C., Willenbrock K., Martin-Subero J.I. High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 2007, 21:780-787.
39. Dutton A., Reynolds G.M., Dawson C.W., Young L.S., PG M. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005, 205:498-506.
40. Georgakis G.V., Yazbeck V.Y., Li Y., Younes A. The mTOR inhibitor temsirolimus (CCI-779) induces cell cycle arrest and autophagy in Hodgkin lymphoma (HL) cell lines and enhances the effect of the PI3-kinase inhibitor LY294002 [abstract]. Blood 2006, 108:2259.
41. Georgakis G.V., Li Y., Rassidakis G.Z., Medeiros L.J., Mills G.B., Younes A. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006, 132:503-511.
42. Jundt F., Raetzel N., Muller C. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005, 106:1801-1807.
43. Zheng Y., Collins S.L., Lutz M.A. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 2007, 178:2163-2170.
44. Del Bufalo D.C.L., Trisciuoglio D. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006, 66:5549-5554.
45. Johnston P.B., Inwards D.J., Colgan J.P., et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010, 85:320-324.
46. Yazbeck V.Y., Buglio D., Georgakis G.V. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 2008, 36:443-450.
47. Fehniger T.A., Larson S., Trinkaus K., et al. A phase II Multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 2009, 114:3693.
48. Kuruvilla J., Taylor D., Wang L., Blattler C., Keating A., Crump M. Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma [abstract]. Blood 2008, 112:3052.
49. Tempescul A., Ianotto J.C., Guillerm G., Berthou C. ESAP-lenalidomide - a highly active regimen in refractory or relapsed Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 2009, 114:4797.
50. Jones R.J., Gocke C.D., Kasamon Y.L. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009, 113:5920-5926.
51. Younes A., Romaguera J., Hagemeister F. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003, 98:310-314.
52. Wedgwood A.R., Fanale M.A., Fayad L.E. Rituximab+ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy [abstract]. Blood 2007, 110:215.
53. Copeland A.R., Cao Y., Fanale M., et al. Final report of a phase-II study of rituximab plus ABVD for patients with newly diagnosed advanced stage classical hodgkin lymphoma: results of long follow up and comparison to institutional historical data. Blood (ASH Annual Meeting Abstracts) 2009, 114:1680.
54. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009, 8:33-40.
55. Younes A., Garg A., BB A. Nuclear transcription factor-kappa B in Hodgkin's disease. Leuk Lymphoma 2003, 44:929-935.
56. Staudt L.M. The molecular and cellular origins of Hodgkin's disease. J Exp Med 2000, 191:207-212.
57. Bargou R.C., Leng C., Krappmann D. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996, 87:4340-4347.
58. Bargou R.C., Emmerich F., Krappmann D. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997, 100:2961-2969.
59. Kato M., Sanada M., Kato I. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009, 459:712-716.
60. Schmitz R., Hansmann M.L., Bohle V. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009, 206:981-989.
61. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003, 8:307-315.
62. Zheng B., Georgakis G.V., Li Y. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004, 10:3207-3215.
63. Younes A., Pro B., Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006, 107:1731-1732.
64. Blum K.A., Johnson J.L., Niedzwiecki D., Canellos G.P., Cheson B.D., Bartlett N.L. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007, 48:1313-1319.
65. Fanale M.A., Fayad L.E., Pro B. A phase I study of bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma [abstract]. Blood 2008, 112:3048.
66. Mendler J.H., Kelly J., Voci S. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008, 19:1759-1764.